Healthcare biotech Facts
& Figures
From
diagnosis to treatment
and in terms of
medicines manufactured,
healthcare biotechnology
is already delivering on
its promises:
-
More
than 325 million
patients have
benefited from
approved medicines
manufactured through
biotechnology and
gene technology to
treat or prevent
heart attacks,
stroke, multiple
sclerosis, breast
cancer, cystic
fibrosis, leukemia,
hepatitis, diabetes
and other diseases.
-
Today, 418 new
biotech medicines
and vaccines are
being tested for
more than 100
diseases, among
which 210 to treat
cancer, 50 to treat
infectious diseases
and 44 to treat
autoimmune
disorders. Biotech
medicines are
estimated to account
for approximately
20% of all marketed
medicines and
represent 50% of all
medicines in the
pipeline.
-
The
industry in Europe
comprises some 1,600
companies and
represented revenues
of approximately €
7.8 billion in 2005.
Increasingly,
diagnostic test kits
and diagnostic
services are using
biotech methods and
reagents.
-
For
the first time in
the history of human
healthcare,
biotechnology is
enabling the
development and/or
manufacturing of
therapies for a
number of rare
diseases with a
genetic origin.
Although
individually rare,
collectively these
diseases affect some
20 to 30 million
Europeans and their
families, with
70-80% having a
genetic component
requiring
biotechnology as
part of the
solution.
-
Biotechnology is
also increasingly
used in healthcare
research, in
combination with
medical devices and
surgical methods.
-
Biotechnology has a
major impact on the
provision of safe
and effective
vaccines against
infectious diseases.
-
Biotechnology also
provides safe
recombinant
alternatives to
proteins derived
from human blood or
tissue.
EU
Commission's Bio4EU
study:
"Consequences,
opportunities &
challenges of
biotech in Europe"
(March
2007)
Biotech medicines
° Biotech companies
focusing on
healthcare biotech
rose from 37 (1996)
to 143 (2005).
° 78% of EU
biotech products are
biotech medicines.
° Biotech medicines
hold a 9% share of
the EU
pharmaceutical
market.
° Growth
rates in
biopharmaceuticals
are twice as high as
non-biotech.
Biotech offers
healthcare:
° unique therapeutic
and diagnostic
solutions;
° unlimited
supplies of
potentially safer
products;
°
superior therapeutic
and diagnostic
approaches.
Critical I Studies on
the Biotech industry in
Europe & the US
-
 Comparative
study on biotech in
Europe - Critical I
comparative
study for EuropaBio
(May 2006)
Critical I 2006
study
|
|
